瑞舒伐他汀钙片治疗高血压脑出血的临床研究

Clinical trial of rosuvastatin calcium tablets in the treatment of hypertensive cerebral hemorrhage

目的观察瑞舒伐他汀钙片治疗高血压脑出血的临床疗效及安全性。方法将134例高血压脑出血患者随机分为对照组65例和试验组69例。对照组予以止血、维持血压稳定、控制颅内压等常规治疗,试验组在对照组治疗的基础上,予以瑞舒伐他汀每次10 mg,qd,口服。2组患者均连续治疗14 d。比较2组患者的临床疗效和美国国立卫生研究院卒中量表(NIHSS)评分,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为89.86%(62例/69例)和75.38%(49例/65例),NIHSS评分分别为(6.63±3.36)和(12.37±6.84)分,差异均有统计学意义(均P<0.05)。试验组的药物不良反应主要有皮疹、关节疼痛、肌肉酸痛和胃肠道反应,对照组的药物不良反应主要有皮疹和胃肠道反应。试验组和对照组的总药物不良反应发生率分别为5.80%和4.62%,差异无统计学意义(P>0.05)。结论瑞舒伐他汀钙片治疗高血压脑出血的临床疗效确切,其能显著改善患者的神经缺损功能状态,且不增加药物不良反应的发生率。

Objective To observe the efficacy and safety of rosuvastatin calcium tablets in the treatment of hypertensive cerebral hemorrhage.Methods A total of 134 patients with hypertensive intracerebral hemorrhage were randomly divided into control group（ n = 65 cases） and treatment group（ n = 69 cases）. Control group was treated with hemostasis,maintaining blood pressure stability and controlling intracranial pressure and so on. Treatment group was given rosuvastatin 10 mg per time,qd,orally,on the basis of control group. Two groups were treated for 14 days. The clinical efficacy, national institutes of health stroke scale（ NIHSS） scores and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of control and control groups were 89. 86%（ 62 cases/69 cases） and 75. 38%（ 49 cases/65 cases）,the NIHSS scores of control and control groups were（ 6. 63 ± 3. 36） and（ 12. 37 ± 6. 84） score,the differences were statistically significant（ all P〈 0. 05）. The adverse drug reactions in treatment group were skin rash,joint pain,muscle soreness and gastrointestinal reaction,which in control group were rashes and gastrointestinal reactions. The total incidences of adverse drug reactions of treatment and control groups were 5. 80% and 4. 62% without significant difference（ P 〉0. 05）. Conclusion Rosuvastatin calcium tablets have a definitive clinical efficacy in the treatment of hypertensive cerebral hemorrhage,which can improve the functional status of nerve defects,without increasing the incidence of adverse drug reactions.